Semax occupies an unusual position in neuropharmacology: it is a fragment of a stress hormone that produces almost none of the hormonal effects of its parent molecule, yet within hours of intranasal administration it triples BDNF mRNA in the hippocampus. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, this seven-amino-acid peptide has been used clinically in Russia for stroke and cognitive disorders for over two decades — and the mechanistic story behind it is one of the cleanest examples of how melanocortin receptor activation can be uncoupled from steroidogenesis and rerouted into neurotrophic signaling.
What Is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is derived from adrenocorticotropic hormone (ACTH), specifically corresponding to the ACTH(4-7) fragment (Met-Glu-His-Phe) extended at the C-terminus with a Pro-Gly-Pro tripeptide. The PGP tail is not arbitrary — it dramatically extends the peptide’s half-life by protecting it from aminopeptidase and carboxypeptidase degradation, allowing it to survive long enough to cross the nasal mucosa and reach the central nervous system intact.[1]
Critically, Semax retains the neurotropic and behavioral activity of ACTH(4-10) but lacks corticotropic activity — it does not stimulate the adrenal cortex or elevate cortisol. This dissociation is what makes it pharmacologically interesting: the melanocortin-receptor-mediated central effects of ACTH are preserved while the peripheral HPA-axis activation is eliminated.[1]
How Semax Works
Melanocortin Receptor Engagement: Semax acts as a ligand at central melanocortin receptors, particularly MC4R and MC3R, which are densely expressed in the prefrontal cortex, hippocampus, hypothalamus, and limbic structures. Unlike α-MSH or full-length ACTH, Semax produces a biased signaling profile that favors neuronal plasticity pathways rather than energy balance or HPA outputs. This melanocortin receptor activation is the upstream initiating event for the downstream BDNF cascade.[2]
BDNF and TrkB Upregulation: The most striking molecular effect of Semax is rapid induction of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB. A single intranasal dose elevates BDNF and TrkB mRNA in the rat hippocampus within hours, with measurable protein-level increases sustained for the following day. NGF (nerve growth factor) and its receptor TrkA are similarly upregulated, indicating that Semax broadly engages the neurotrophin signaling network rather than acting on BDNF alone.[3]
Downstream Plasticity Signaling: BDNF binding to TrkB triggers the canonical PI3K-Akt, MAPK/ERK, and PLCγ pathways. These cascades converge on CREB phosphorylation, dendritic spine remodeling, and long-term potentiation — the cellular substrate of learning and stress-resilient cognition. In the prefrontal cortex specifically, BDNF-TrkB signaling is required for executive function and for recovery of dendritic complexity after chronic stress, which provides a mechanistic rationale for Semax’s reported pro-cognitive effects.[4]
Modulation of Monoaminergic Tone: Beyond neurotrophins, Semax influences dopaminergic and serotonergic systems. It potentiates dopamine and serotonin turnover in cortical regions and modulates enkephalin degradation by inhibiting enkephalinases, indirectly raising endogenous opioid tone. These effects likely contribute to its observed anxiolytic and antidepressant-like profile in animal models.[2]
Research Findings
Hippocampal Neurotrophin Induction: Dolotov and colleagues demonstrated that intranasal Semax in rats produced rapid and sustained upregulation of BDNF and TrkB expression in the hippocampus, with BDNF protein increases evident within hours of a single dose. This was the first direct molecular evidence that an ACTH(4-7) analog could function as a neurotrophin inducer in vivo.[3]
Ischemic Stroke Recovery: Semax has been studied extensively in the context of acute ischemic stroke. Gusev and colleagues conducted a randomized controlled trial in patients with hemispheric ischemic stroke and reported accelerated neurological recovery and improved functional outcomes in the Semax-treated group compared with placebo, with the effect attributed to neurotrophic and neuroprotective mechanisms.[5]
Cognitive and Attentional Effects: In healthy human volunteers performing demanding cognitive tasks, Semax has been shown to improve attentional performance, working memory, and resistance to mental fatigue. These effects appear most pronounced under conditions of cognitive load and operator stress, consistent with the idea that the peptide preferentially supports prefrontal function when neurotrophic demand is high.[1]
Transcriptomic Signature: Whole-transcriptome analyses of Semax-treated rat brain tissue reveal modulation of genes involved in vascular and immune system function, neurotransmission, and neurotrophin signaling — including BDNF, NGF, and several immediate-early genes. This broad transcriptional fingerprint suggests Semax is acting upstream as a system-level neuromodulator rather than as a narrow receptor agonist.[4]
Safety Profile
Semax has been used clinically in Russia since 1994 and has accumulated decades of human exposure data in stroke, transient ischemic attack, optic nerve disorders, and ADHD-like presentations in children. The reported safety profile is favorable: it does not stimulate adrenal cortisol release, does not produce significant cardiovascular effects, and does not appear to induce tolerance or dependence in animal studies. The most common reported effects are mild and include transient nasal irritation from the intranasal formulation.[1]
Importantly, because Semax lacks corticotropic activity, it does not carry the metabolic, immunosuppressive, or HPA-disruptive risks associated with exogenous ACTH or glucocorticoids. The peptide is rapidly metabolized after central uptake — the PGP tail extends half-life sufficiently for absorption and CNS entry but does not produce long-term accumulation.
It should be emphasized that Semax is not approved by the FDA in the United States. Its clinical evidence base, while substantial, is largely Russian-language literature, and the peptide has not been subjected to the large multicenter Phase III trials that Western regulatory frameworks require. Clinicians considering it should weigh this regulatory context carefully.
Semax vs Other Neurotrophic Strategies
vs Direct BDNF Administration: Recombinant BDNF cannot meaningfully cross the blood-brain barrier and has an extremely short plasma half-life, which is why decades of attempts to develop BDNF itself as a therapeutic have failed. Semax sidesteps this problem entirely by acting as a small peptide that crosses the nasal-to-brain pathway and induces endogenous BDNF synthesis at the tissue level — a more physiological approach than supplying exogenous neurotrophin.
vs Cerebrolysin: Cerebrolysin is a porcine brain-derived peptide preparation also used in stroke recovery. It contains a mixture of low-molecular-weight peptides with neurotrophin-like activity. Semax is a defined single molecule with a known sequence and a more characterized receptor mechanism, which gives it a cleaner pharmacological profile, though Cerebrolysin has a larger Western evidence base.
vs Selank: Selank, also developed at the Institute of Molecular Genetics, is a heptapeptide derived from tuftsin and shares the PGP stabilizing tail. Selank is primarily anxiolytic, acting on GABAergic and enkephalin systems with weaker direct neurotrophic induction. The two peptides are often discussed together but engage different upstream receptors — Selank is not a melanocortin ligand.
vs SSRIs: Chronic SSRI administration eventually upregulates BDNF in the hippocampus, and this delayed neurotrophic effect is now widely thought to underlie the lag in clinical response to antidepressants. Semax appears to induce BDNF directly and rapidly via melanocortin signaling rather than indirectly through monoamine elevation, suggesting a fundamentally different temporal profile of neurotrophic engagement.
References
- Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. “Design and investigation of an ACTH(4-10) analog lacking D-amino acids and hydrophobic radicals.” Neuroscience and Behavioral Physiology. 1995;25(3):234-240.
- Eremin KO, Kudrin VS, Saransaari P, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. “Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry. 2006;97 Suppl 1:82-86.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. “The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.” BMC Genomics. 2014;15:228.
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. “Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 1997;97(6):26-34.
